Motexafin lutetium

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Motexafin lutetium
Motexafin lutetium.png
Identifiers
CAS number 246252-04-0 YesY
PubChem 3081907
Jmol-3D images Image 1
Properties
Molecular formula C52H72LuN5O14
Molar mass 1,166.12 g mol−1
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 YesY (verify) (what is: YesY/N?)
Infobox references

Motexafin lutetium is a texaphyrin, marketed as Antrin by Pharmacyclics Inc.

It is a photosensitiser for use in photodynamic therapy to treat skin conditions and superficial cancers.

It has also been tested for use in photoangioplasty (photodynamic treatment of diseased arteries).[1]

It is photoactivated by 732 nm light which allows greater depth of penetration.[2]

Clinical trials[edit]

Phase II clinical trials were in progress in 1999.[3]

A phase I trial for prostate cancer reported in 2009.[4]

References[edit]

  1. ^ Pharmacyclics Announces Final Phase 1 Results of Antrin Phototherapy For Coronary Artery Disease, 2002
  2. ^ http://findarticles.com/p/articles/mi_qa3931/is_200909/ai_n42040200/pg_9/ Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy Photochemistry and Photobiology, Sep/Oct 2009. by O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T
  3. ^ Antrin Photoangioplasty Phase II Clinical Trial Patient Treated During Live Case Demonstration at TCT, 1999
  4. ^ Patel, H; Mick, R; Finlay, J; Zhu, TC; Rickter, E; Cengel, KA; Malkowicz, SB; Hahn, SM; Busch, TM (2008). "Motexafin lutetium-photodynamic therapy of prostate cancer: Short and long term effects on PSA". Clinical cancer research : an official journal of the American Association for Cancer Research 14 (15): 4869–76. doi:10.1158/1078-0432.CCR-08-0317. PMC 2680073. PMID 18676760.